-
TECregen AG
-
-
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups -
Social networks
1,478 -
Activities
-
Technologies
-
Entity types
-
Location
Hochbergerstrasse 60C, 4057 Basel, Switzerland
Basel
Switzerland
-
Employees
Scale: 2-10
Estimated: 14
-
Engaged catalyst
2
0 0 -
Added in Motherbase
7 months ago
-
Value proposition
TECregen is dedicated to advancing immuno-rejuvenation by developing next generation therapies to regenerate the thymus.
TECregen is pioneering thymus rejuvenation to address conditions driven by impaired T-cell responses. The company’s innovative approach focuses on revitalizing and expanding thymic epithelial cells (TECs) to replenish T cells and achieve durable improvements in immune function. By developing a pipeline of differentiated thymopoietic biologics, TECregen aims to strengthen immune recovery following transplantation or cytotoxic therapy, promote immune health, and enhance immune surveillance against cancer, ushering in a new era of immunotherapy.
-
Home :: TECregen
https://tecregen.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
HTGF | High-Tech Gründerfonds
Venture Capital and Private Equity Principals (Auto) |
HTGF | High-Tech Gründerfonds
Venture Capital and Private Equity Principals (Auto) |
Other
31 Dec 2025 |
|
|
Boehringer Ingelheim
Pharmaceutical, Pharmaceutical Manufacturing (Auto), Animal Health |
Boehringer Ingelheim
Pharmaceutical, Pharmaceutical Manufacturing (Auto), Animal Health |
Other
31 Dec 2025 |
|
|